Dx&Vx said it is participating in overseas research led by Coree Group on finding new biomarkers to develop therapeutics for diabetes and obesity.
Dx&Vx has started developing microbiome-based diabetes and obesity treatments.
To search for biomarkers, Agostino Gemelli University Policlinic, an Italy-based hospital, and Coree Group are conducting a clinical study, named, "Comparing diet and lifestyle using innovative technology and multi-omics analysis in healthy, diabetic and obese people.
According to Dx&Vx, the clinical study started in 2018 when Agostino Gemelli University Policlinic established a biobank for mothers and fetuses with the support of Lim Jong-yoon, president of Hanmi Pharmaceutical and majority shareholder of Dx&Vx.
“Professor Antonio Gasbarrini at Agostino Gemelli University Policlinic, who is leading the study, is a pioneer in inflammatory and oncological diseases such as the gastrointestinal tract, liver, and pancreas using the latest innovations such as fecal microbiota transplantation,” Dx&Vx said. “The clinical study has made about 50 percent progress.”
The goal is to determine how the intestinal microbiome and its metabolites interact with the host in metabolic diseases such as diabetes and obesity, it added.
Dx&Vx CEO Park Sang-tae said the company will use new biomarkers to develop next-generation probiotic products and commercialize digital prevention solutions.
In cooperation with Coree Group, Dx&Vx plans to secure new pipelines such as preventive treatment solutions for improving the symptoms of metabolic syndrome by regulating the intestinal microbial environment, Park added.
Formerly known as CancerRop, the company started anew after changing its name to Dx&Vx in December 2021.
Lim is currently the largest shareholder of Cancerrop, with 5,614,823 shares, or a 19.57 percent stake, after acquiring the stake by investing in-kind shares of Hanmi Science worth 20 billion won ($17.1 million) in October of last year.
Source: Korea Biomedical Review